Discovery of a Selective S1P(1) Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate

[Image: see text] Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors (S1P(1) and S1P(3−5)). It has be...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Demont, Emmanuel H., Andrews, Benjamin I., Bit, Rino A., Campbell, Colin A., Cooke, Jason W. B., Deeks, Nigel, Desai, Sapna, Dowell, Simon J., Gaskin, Pam, Gray, James R. J., Haynes, Andrea, Holmes, Duncan S., Kumar, Umesh, Morse, Mary A., Osborne, Greg J., Panchal, Terry, Patel, Bela, Perboni, Alcide, Taylor, Simon, Watson, Robert, Witherington, Jason, Willis, Robert
Format: Artigo
Langue:Inglês
Publié: American Chemical Society 2011
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4018134/
https://ncbi.nlm.nih.gov/pubmed/24900328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml2000214
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires